Drug-induced subacute cutaneous lupus erythematosus associated with nab-paclitaxel therapy

作者：Lamond N W D^*; Younis T; Purdy K; Dorreen M S

来源：Current Oncology, 2013, 20(5): E484-E487.

DOI：10.3747/co.20.1546

• Nanoparticle albumin-bound paclitaxel
• nab-paclitaxel
• subacute cutaneous lupus erythematosus
• cutaneous drug reactions

Drug-induced lupus erythematosus (DILE) syndromes are documented complications of chemotherapeutic agents, including paclitaxel. Subacute cutaneous lupus erythematosus (SCLE) is a distinct DILE syndrome presenting with characteristic annular or papulosquamous skin lesions in a photosensitive distribution with associated high anti-SSA titres. Previously, DILE syndromes complicating paclitaxel therapy have been attributed to polyethoxylated castor oil (Kolliphor EL: BASF, Ludwigshafen, Germany), the biologic solvent included in the drug%26apos;s original formulation (Taxol: Bristol-Myers Squibb, Montreal, QC), rather than the parent chemotherapy molecule. Here, we report a characteristic case of drug-induced SCLE complicating treatment with nanoparticle albumin bound (nab)-paclitaxel (Abraxane: Celgene, Summit, NJ, U.S.A.), a solvent-free taxane formulation. The pertinent English-language literature is also discussed. This case report is the first to link solvent-free paclitaxel with SCLE, and it suggests that the parent molecule is responsible for the reaction.

• 出版日期2013-10